New Delhi (ABC Live):India has strong skills in vaccines, low-cost drugs, research and drug making. However, biopharmaceuticals need a separate policy path.

Biopharmaceuticals are medicines made from living cells or living systems. They include vaccines, insulin, biosimilars, monoclonal antibodies, cell therapy, gene therapy and other advanced bio medicines.

However, these products are not like normal chemical drugs. They need strict quality checks, trained people, clean plants, cold chains and strong safety data.

Therefore, India should not treat bio medicines only as another form of generic drugs. Instead, India needs a clear national plan that links research, rules, making, public buying, health cover, exports and patient access.

This issue also connects with ABC Live’s earlier analysis of Ayushman Bharat and AB-PMJAY, because costly bio medicines will need stronger public health-cover systems.

India has already taken some key steps. The Union Cabinet approved the BioE3 Policy — Biotechnology for Economy, Environment and Employment on 24 August 2024. Moreover, the National Biopharma Mission supports early work on bio medicines.

In addition, the Central Drugs Standard Control Organisation (CDSCO) has issued a separate path for similar biologics. However, India still needs one joined-up National Biopharmaceuticals Policy.

Key Points

Area Present Position Main Gap Policy Need
Research India has DBT, BIRAC and the National Biopharma Mission. However, many ideas do not become products. Therefore, India needs more support for scale-up.
Manufacturing India has vaccine and biosimilar strength. However, advanced plants are costly. Therefore, India needs shared bio-making units.
Regulation CDSCO regulates biologics and similar biologics. However, firms need clearer timelines. Therefore, CDSCO needs more special bio-medicine skill.
Patient access Biosimilars can lower costs. However, many patients still cannot afford biologics. Therefore, public hospitals should use safe biosimilars.
Exports India has a strong pharma name. However, biologics need higher trust. Therefore, quality must become an export tool.
Skills BioE3 links biotech with jobs. However, India lacks enough trained people. Therefore, India needs a bio-medicine skills mission.

Why ABC Live Is Publishing This Report Now

India’s biotech policy has entered a new phase. Earlier, the main focus was research and low-cost drugs. However, the new focus is high-end bio-making, jobs and global supply.

Official data says India’s bioeconomy has grown fast. In addition, the sector now has thousands of biotech startups. Therefore, the policy question has changed.

India no longer needs only more labs. Instead, India needs a full plan that turns lab work into safe, useful, low-cost and export-ready bio medicines.

This concern also links with ABC Live’s health-policy coverage, including its report on GLP-1 drugs for diabetes and obesity. In that report, access, safety, pricing and misuse were key public-health concerns.

Moreover, other countries are moving fast. The United States, European Union, United Kingdom, South Korea and Singapore are building strong bio-medicine systems. As a result, India must act now.

1. What Are Biopharmaceuticals?

1.1 Simple Meaning

Biopharmaceuticals are medicines made from living cells or living systems. They are also called biologics or bio medicines.

They include:

  • Vaccines
  • Insulin
  • Biosimilars
  • Monoclonal antibodies
  • Cell therapy
  • Gene therapy
  • Blood products
  • Protein-based drugs
  • Messenger ribonucleic acid medicines

1.2 Why They Matter

These medicines matter because they can treat hard diseases. For example, they help in cancer, diabetes, immune disease, rare disease and some gene-based illness.

For a related public-health example, ABC Live has also explained how GLP-1 drugs for diabetes and obesity moved from specialist treatment to a wider safety and access debate.

However, many bio medicines are costly and hard to make. Therefore, policy support is very important.

1.3 Why They Need Special Rules

Normal drugs are made by chemical steps. However, biologics come from living systems.

As a result, two products may not be exact copies. Therefore, a biosimilar must prove that it is very close to the first approved biologic.

This is why India needs stronger rules, better data and more trained people.

2. How Biopharmaceuticals Differ From Regular Medicines

Biopharmaceuticals are different from regular medicines. Regular medicines are usually made through chemical steps. However, biopharmaceuticals are made from living cells, proteins, genes or tissues.

Therefore, India cannot regulate, make, price or buy biopharmaceuticals exactly like ordinary tablets or capsules.

2.1 Simple Difference

Point Regular Medicines Biopharmaceuticals
Main source Made through chemical steps Made from living cells or living systems
Size Usually small and simple Large, complex and sensitive
Examples Paracetamol, aspirin, antibiotics Vaccines, insulin, biosimilars, cell therapy
Copy version Generic medicine Biosimilar
Making process More predictable Highly sensitive to process changes
Testing need Chemical match is central Quality, safety, effect and similarity are central
Storage Often stable at room temperature Many need cold-chain storage
Patient risk Side effects can occur Immune reactions also need close tracking
Cost Often cheaper after patent expiry Often costly even after competition

2.2 Why Generics and Biosimilars Are Not the Same

A generic drug copies a chemical medicine. If it has the same active ingredient, strength and body effect, regulators can approve it through a simpler route.

However, a biosimilar is different. It is not an exact copy in the same way. Since biologics come from living systems, small changes can arise during production.

Therefore, a biosimilar must prove that it is highly similar to the reference biologic. It must also show no major difference in safety, purity and effect.

As a result, biosimilar approval needs deeper scientific review.

2.3 Why Manufacturing Is More Complex

Regular medicines can often be made through controlled chemical steps. However, biopharmaceuticals depend on living cells.

As a result, even small changes in the process can affect the final product. For example, changes in cell growth, heat, cleaning, storage, transport or contamination control can affect quality.

Therefore, biopharmaceutical manufacturing needs:

  • Sterile facilities
  • Cell-line control
  • Bioreactors
  • Protein cleaning systems
  • Cold-chain transport
  • Batch-level testing
  • Strong quality checks
  • Long-term safety tracking

2.4 Why Pricing and Access Are Different

Regular medicines often become cheaper after generic competition enters the market. However, biopharmaceuticals may remain costly even after biosimilars arrive.

This happens because production and quality systems remain expensive. Therefore, India needs a special access plan.

Public hospitals, government buying, insurance schemes and cancer-care programmes should use quality-assured biosimilars to reduce treatment costs.

However, price cuts should not reduce safety. Therefore, India must balance low cost, quality and patient trust.

3. India’s Present Policy Base

3.1 BioE3 Policy

The BioE3 Policy — Biotechnology for Economy, Environment and Employment is India’s key new biotech policy.

BioE3 seeks to boost high-end bio-making. Moreover, it links biotech with jobs, green growth and new tools such as artificial intelligence.

For bio medicines, the key area is precision biotherapeutics. However, India’s bio-policy future also depends on how it manages biological resources, research access and public repositories.

ABC Live discussed this wider issue in its analysis of India’s Biodiversity Repositories Notification.

In addition, the Biomanufacturing and Biofoundry Initiative can help firms move from lab work to larger plants.

Therefore, BioE3 can become the base for India’s bio-medicine growth.

3.2 National Biopharma Mission

The National Biopharma Mission supports joint work between industry and research bodies.

It is run by the Biotechnology Industry Research Assistance Council (BIRAC). Moreover, it supports early work on bio-medicine products.

This mission matters because many good ideas fail before clinical use. Therefore, public support can reduce risk and bring in private money.

However, India now needs the next step. It must support scale-up, trials, rule filing, public buying and global entry.

3.3 CDSCO Rules for Similar Biologics

The CDSCO biologicals page gives rule material on biologics and similar biologics.

In May 2025, CDSCO placed the Revised Guidelines on Similar Biologics, 2025 for comments.

This matters because biosimilars are not simple copies. They need proof on quality, safety, strength and patient response.

Therefore, India must make rules strong and clear at the same time.

4. Main Policy Problem

4.1 India Has Many Schemes, But No Single Plan

India has BioE3, the National Biopharma Mission, CDSCO rules, public labs and private firms.

However, these parts do not yet work as one full system. Therefore, India needs one national policy for bio medicines.

This point also connects with ABC Live’s report on India’s Biodiversity Repositories Notification, where research systems, records, access rules and safeguards were central issues.

4.2 Research Does Not Always Reach Patients

India has strong science talent. However, many lab ideas do not become products.

The main reason is cost. For example, firms need money for testing, plant design, trials and rule filing.

Therefore, India needs more support for the middle stage between lab and market.

4.3 Manufacturing Is Costly

Biologics need clean plants, cell lines, bioreactors, cold chains and strict batch checks.

As a result, small firms face high costs. Therefore, India needs shared pilot plants and public-private bio-making parks.

4.4 Rules Need More Clarity

Rules must protect patients. However, firms also need clear timelines and early advice.

If the path is unclear, investors may avoid risky projects. Therefore, CDSCO needs more trained bio-medicine experts and clear review steps.

4.5 Access Is Still Weak

Biologics can change treatment for cancer, diabetes and immune disease. However, many families cannot afford them.

Biosimilars can reduce the cost. However, approval alone is not enough. Therefore, biosimilars must link with public hospitals, health cover and public buying.

4.6 Quality Will Decide Export Trust

India has a strong name in generic drugs. However, biologics face a higher trust test.

Global buyers check plant quality, batch data, safety records and inspection history. Therefore, India must treat quality as a trade strength.

5. Policy Goals for India

5.1 Make Safe and Low-Cost Bio Medicines

India should make bio medicines that are safe and affordable. Moreover, it should focus on the needs of Indian patients and the Global South.

5.2 Build Local Bio-Making Strength

India should reduce import need for key inputs. For example, it should build local supply for cell media, test kits, plant parts and other critical goods.

In addition, India’s long-term bioeconomy strength also depends on how it protects and studies its natural resource base. ABC Live explained this wider civilisational and ecological link in India’s Gondwanaland origins and biodiversity.

Therefore, local supply chains and biological resource protection must both be part of the policy.

5.3 Improve Patient Access

Public hospitals should get safe biosimilars at fair prices. In addition, health cover schemes should include key bio medicines.

Therefore, this policy brief should be read with ABC Live’s analysis of Ayushman Bharat and AB-PMJAY, because public health cover will shape whether costly biologics reach ordinary patients.

As a result, poor and middle-class patients can get better care.

5.4 Build Export Trust

India should become a trusted source of biosimilars, vaccines and biologics.

However, exports will grow only if quality stays high. Therefore, India must build global-level quality systems.

5.5 Protect Ethics and Safety

Cell therapy, gene therapy and data-linked biotech need strong ethics.

Therefore, India must protect consent, trial data, genetic data and long-term patient safety.

5.6 Create Skilled Jobs

BioE3 links biotech with jobs. Therefore, India should train people in bio-making, quality checks, trial work, safety data and cold-chain work.

6. Global Best Practices: What India Can Learn

6.1 Why Global Comparison Matters

India has made progress. However, other countries have built more mature systems.

Therefore, India should learn from them. At the same time, India should not copy them blindly.

India needs a model that combines global trust with local access.

6.2 Global Practice Table

Area India Today Global Practice Lesson for India
National plan India has BioE3 and the National Biopharma Mission. However, it lacks one bio-medicine policy. The European Union links drug policy, biotech, research and patient access. Therefore, India needs a National Biopharmaceuticals Policy.
Biosimilar rules CDSCO has similar biologics rules. WHO, EMA, FDA and MHRA use strong similarity-based rules. Therefore, India should align with global science.
Rule clarity India is improving. However, firms need clearer advice. FDA and MHRA give guidance for firms. Therefore, CDSCO should start formal advice meetings.
Public trust India has limited public notes on approvals. EMA explains biosimilars in simple terms. Therefore, India should publish public approval summaries.
Access India has biosimilars. However, access remains uneven. Europe links biosimilars with health-system use. Therefore, India should link approval with public buying.
Manufacturing India has strong capacity. However, scale-up is hard. South Korea and Singapore built strong clusters. Therefore, India should build shared bio-making hubs.
Safety data India has safety systems. However, bio-medicine data is weak. WHO and EMA stress safety after approval. Therefore, India needs a national biologics registry.

6.3 United States: Clear Rules and Faster Review

The United States Food and Drug Administration gives detailed guidance for biosimilars.

Moreover, the FDA has moved to make biosimilar development faster and less costly.

However, India should not copy the United States price model. Many biologics in the United States remain very costly.

Therefore, India should take rule clarity from the United States. At the same time, India should keep patient cost low.

6.4 European Union: Trust Through Public Explanation

The European Medicines Agency has a mature biosimilar system.

Moreover, it explains biosimilars in public language. This helps doctors and patients trust these products.

Therefore, India should publish simple approval summaries. These summaries should say why the product was cleared, what proof was checked and what safety duties apply.

As a result, doctors, hospitals, insurers and patients will gain more trust.

6.5 United Kingdom: Clear Licensing Path

The United Kingdom gives clear guidance for biosimilar licensing.

Therefore, firms can plan better. They know what data, tests and steps may be needed.

India should follow this approach. For example, CDSCO can issue product-wise guidance for insulin, monoclonal antibodies, cell therapy and gene therapy.

In addition, CDSCO should update these notes often. As a result, firms will face less doubt.

6.6 WHO: Global Minimum Standard

The World Health Organization gives global principles for biosimilars.

Its approach focuses on quality, safety and proof of similarity. Therefore, WHO guidance can help India match global norms.

However, India should also add its own public-health needs. For example, India should add low-cost access, public buying, batch tracking and strong safety checks.

6.7 South Korea and Singapore: Scale and Clusters

South Korea shows how biosimilars can become an industry strength. It has built scale, exports and global filing skill.

Similarly, Singapore shows how high-quality clusters can attract global firms.

However, India cannot copy either model fully. India is larger and has wider state needs.

Therefore, India should build regional clusters in Hyderabad, Pune, Bengaluru, Ahmedabad, Mumbai and Delhi-National Capital Region.

However, these clusters must not become only land projects. Instead, they should provide labs, testing units, trial links, rule help and trained staff.

7. ABC Live Policy Analysis

7.1 India Should Not Treat Bio Medicines Like Generic Drugs

India’s drug success came mainly from chemical generics. However, bio medicines work in a different way.

A generic tablet can match a chemical formula. However, a biosimilar must show that it is highly similar to the first biologic.

Therefore, India needs a biologics-first policy. It should not just stretch the old generic model.

7.2 BioE3 Gives India a Timely Base

BioE3 links biotech with jobs, green growth, artificial intelligence and new industry.

However, BioE3 now needs a clear bio-medicine roadmap. This roadmap should include funds, timelines, product groups, rule steps and state roles.

Therefore, BioE3 should become the main umbrella for a National Biopharmaceuticals Policy.

7.3 Biosimilars Can Lower Treatment Cost

Cancer drugs, insulin products and immune disease biologics are often costly.

Therefore, biosimilars can help many patients. However, India must not allow a weak-quality race.

Low price without strong quality can harm trust. Therefore, low cost and high quality must move together.

7.4 Public Buying Can Shape the Market

Public hospitals can create demand for safe biosimilars.

Moreover, as ABC Live discussed in Ayushman Bharat and AB-PMJAY, public health schemes need cleaner data, timely payments and stronger patient safeguards.

However, tenders should not use only the lowest price. Instead, they should check quality record, cold chain, batch data, safety system and supply strength.

As a result, patients can get both low cost and safe care.

7.5 India Needs Better Safety Data

Bio medicines need long-term safety data.

Therefore, India needs a national data system for product use, batch numbers, side effects, switching and patient results.

Without this data, trust will remain weak.

8. Policy Recommendations

8.1 Create a National Biopharmaceuticals Policy

India should issue a dedicated National Biopharmaceuticals Policy.

This policy should link:

  • BioE3
  • National Biopharma Mission
  • CDSCO rules
  • Public hospitals
  • Health cover schemes
  • State biotech parks
  • Industry
  • Research bodies
  • Export support

Therefore, India can move from scattered action to one joined-up plan.

8.2 Launch a BioE3 Bio-Medicine Mission

The government should create a focused mission under BioE3.

It should support:

  • Cell-line work
  • Process work
  • Pilot plants
  • Trial readiness
  • Rule filing
  • Quality systems
  • Biofoundry access
  • Artificial intelligence tools

As a result, more Indian ideas can become real products.

8.3 Strengthen CDSCO’s Biologics Team

CDSCO should build a stronger biologics team.

It should provide:

  • Clear review timelines
  • Product-wise guidance
  • Early advice meetings
  • Online filing
  • Public approval summaries
  • Strong safety follow-up
  • Global rule alignment

Therefore, India can protect patients and reduce delay.

8.4 Build Shared Bio-Making Facilities

India should create shared facilities for startups and mid-sized firms.

These units should offer:

  • Good Manufacturing Practice pilot plants
  • Bioreactor access
  • Lab testing
  • Fill-finish support
  • Stability testing
  • Reference standard support
  • Training labs

Moreover, these units should provide real working support, not just buildings.

8.5 Link Biosimilars With Public Health Schemes

India should create a biosimilar access plan for costly disease areas.

It should focus on:

  • Cancer
  • Diabetes
  • Kidney disease
  • Immune disease
  • Rare disease where biologics are used

Therefore, public buying and health cover can help patients get safe biosimilars.

8.6 Create a National Biologics Registry

India should create a registry for biologics and biosimilars.

It should record:

  • Product name
  • Batch number
  • Disease use
  • Patient result
  • Side effect
  • Switching data
  • Long-term safety issue

As a result, India can build patient safety and global trust.

8.7 Make Quality an Export Tool

India should support firms that invest in high quality.

Support may include:

  • Inspection readiness help
  • Quality training
  • Export market support
  • Global filing help
  • Faster testing support

Therefore, quality should become India’s export strength.

8.8 Build Bio-Medicine Skills

India should launch skill courses with firms, labs, hospitals and rule bodies.

The courses should cover:

  • Bio-making
  • Cell culture
  • Protein cleaning
  • Quality checks
  • Trial work
  • Safety reports
  • Cold-chain work
  • Data analysis
  • Artificial intelligence in biotech

Moreover, these courses should link directly with jobs.

This skills push should also connect with India’s wider research and innovation agenda, which ABC Live covers through its ABC Research section.

9. Suggested Institutional Model

9.1 National Biopharmaceuticals Coordination Council

India should create a National Biopharmaceuticals Coordination Council.

Body Role
Department of Biotechnology Research and BioE3 link
BIRAC Startup and industry-academia support
CDSCO Rules and approvals
ICMR Clinical research and ethics
Department of Pharmaceuticals Industry support
NPPA Price and access oversight
Ministry of Health Public buying and patient access
State governments Parks and hospitals
Industry Making, exports and new products
Public hospitals Use data and patient feedback

9.2 Council’s Main Job

This council should not become only an advisory group.

Instead, it should track work, remove delays and publish a yearly progress report.

Therefore, policy will stay active after launch.

10. Roadmap for Action

10.1 First 12 Months

India should issue the National Biopharmaceuticals Policy.

In addition, it should create the BioE3 Bio-Medicine Mission. It should also map current biologics plants and choose five priority biosimilar areas.

Moreover, CDSCO should start advice meetings for biologics firms.

10.2 12 to 36 Months

India should build shared pilot plants.

In addition, it should launch the National Biologics Registry and create public buying rules for biosimilars.

Moreover, it should fund 50 to 100 scale-up projects and start skill courses in key clusters.

10.3 36 to 60 Months

India should expand biosimilar exports.

Similarly, it should support Indian approvals in global markets. It should also build local input supply chains.

As a result, India can become a Global South hub for safe and low-cost bio medicines.

11. Risks and Concerns

11.1 Weak Rules Can Harm Patients

If approval rules become too weak, poor products may enter the market.

Therefore, India must avoid shortcuts.

11.2 High Prices Can Block Access

If biologics remain costly, patients will not benefit.

Therefore, price policy must balance reward, access and fair returns.

11.3 Import Dependence Can Hurt Supply

India may make final products but still depend on imported inputs.

Therefore, local supply chains need support.

11.4 Data Gaps Can Reduce Trust

If safety data is weak, doctors may avoid switching patients to biosimilars.

Therefore, India needs stronger follow-up after approval.

11.5 Skill Gaps Can Slow Growth

Bio-making needs trained people.

Therefore, skills must be treated as core policy infrastructure.

12. ABC Live Policy Position

India should treat biopharmaceuticals as a health, science, industry, jobs and export priority.

However, the policy should not focus only on exports. It should also reduce treatment costs for Indian patients.

Similarly, the policy should not focus only on low prices. It must also protect quality, safety, trust and new ideas.

Therefore, India needs a balanced model:

Low-cost innovation + strong rules + public access + global quality + skilled jobs.

BioE3 gives India the base. However, India now needs a dedicated National Biopharmaceuticals Policy.

As a result, India can move from being a low-cost drug supplier to becoming a trusted global hub for safe, high-quality and affordable bio medicines.

This wider policy shift also links with ABC Live’s continuing coverage of India, Health and research-led public-interest reporting.

Frequently Asked Questions

What are biopharmaceuticals?

Biopharmaceuticals are medicines made from living cells or living systems. They include vaccines, insulin, biosimilars, monoclonal antibodies, cell therapy and gene therapy.

Why does India need a separate policy?

India’s old pharma model focuses mainly on chemical generics. However, bio medicines need different rules, plants, skills and safety checks.

Therefore, India needs a separate policy.

What is BioE3?

BioE3 means Biotechnology for Economy, Environment and Employment. It aims to support high-end bio-making, jobs, biofoundries and biotech-led growth.

What is the National Biopharma Mission?

The National Biopharma Mission supports early work on bio-medicine products. It links industry, labs and public support.

What is the biggest policy gap?

The biggest gap is the lack of one joined-up plan.

India has research, rules, firms and public need. However, these parts must work together.

Also Read ABC Live Reports

Sources and Resources

  1. Press Information Bureau: Cabinet approves BioE3 Policy for fostering high-performance biomanufacturing
  2. Department of Biotechnology: BioE3 Biomanufacturing Initiative
  3. BIRAC: National Biopharma Mission
  4. CDSCO: Biologicals Guidance Page
  5. CDSCO: Revised Guidelines on Similar Biologics, 2025
  6. Press Information Bureau: India’s Bioeconomy Growth
  7. World Health Organization: Guidelines on Evaluation of Biosimilars
  8. European Medicines Agency: Biosimilar Medicines Overview
  9. United States FDA: Biosimilars Industry Information and Guidance
  10. United Kingdom Government: Guidance on the Licensing of Biosimilar Products

Publication Note

This policy brief forms part of ABC Live’s research-led public policy coverage.

It aims to make complex biotechnology and health-policy issues simple for readers, policymakers, industry, researchers and public-health bodies.